Diabetic Neuropathy Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 23 studies associated with Diabetic Neuropathy.
Here is a small sampling of Diabetic Neuropathy studies by title:
- Spinal cannabinoid CB1 or CB2 receptors activation attenuates mechanical allodynia in streptozotocin-induced diabetic rats
- A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
- Cannabidiol (CBD) For the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet: A Placebo-Controlled, Double-Blind, Randomized Trial
- (+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB 1 R antagonist/CB 2 R agonist that prevents diabetic nephropathy in mice
- A Secondary Analysis from a Randomized Trial on the Effect of Plasma Tetrahydrocannabinol Levels on Pain Reduction in Painful Diabetic Peripheral Neuropathy
Components of the Diabetic Neuropathy Research Dashboard
- Dosing information available for Diabetic Neuropathy
- Chemotype guidance for treating Diabetic Neuropathy with cannabis
- Synopsis of cannabis research for Diabetic Neuropathy
- Individual study details for Diabetic Neuropathy
Ready to become a subscriber? Go to our PRICING page.
Select New Condition
Overview - Diabetic Neuropathy
Description of Diabetic Neuropathy
Diabetic-related neuropathies refer to a group of nerve disorders caused by long-term high blood sugar levels in people with diabetes. There are several types of diabetic neuropathies, including large and small fiber neuropathies, peripheral and proximal neuropathies, autonomic neuropathies, and focal neuropathy.
Peripheral neuropathy is the most common type of diabetic neuropathy, affecting the nerves in the feet, legs, hands, and arms. It can cause symptoms such as numbness, tingling, burning, or stabbing pain in the affected areas, as well as weakness and loss of coordination.
Autonomic neuropathy affects the nerves that control involuntary functions such as digestion, heart rate, and blood pressure. As a result, it can cause symptoms such as nausea, vomiting, diarrhea, constipation, bladder problems, and sexual dysfunction.
Proximal neuropathy affects the nerves in the hips, thighs, and buttocks, causing muscle weakness and pain.
Focal neuropathy affects a specific nerve or group of nerves, causing sudden weakness or pain in the affected area.
Diabetic neuropathies can be challenging to treat and significantly impact an individual's quality of life. Treatment may include blood sugar control, medications to manage symptoms, physical therapy, and lifestyle changes such as regular exercise and a healthy diet.
Prevention is critical in managing diabetic neuropathies, and maintaining reasonable blood sugar control can help prevent or delay the onset of nerve damage. Regular check-ups and monitoring of blood sugar levels are also crucial for the early detection and management of diabetic neuropathies.
Disease Classification
Condition: Pain - Neuropathy - DiabeticDisease Family: Metabolic Disorder
Organ System: Endocrine System, Nervous System
ICD-10 Chapter: Endocrine, Nutritional and Metabolic Diseases
ICD-10 Code: E11.4
Diabetic Neuropathy Symptoms:
Pain in extremities (e.g. tingling, numbness, burning, electric), weakness in affected limbs, ataxia, may affect organs and cause symptoms accordingly (e.g. bladder- incontinence)Also known as:
Diabetes mellitus with neurological complications, Type 2 diabetes mellitus with unspecified diabetic neuropathy, Diabetes type 2 with peripheral neuropathy, Diabetes type 2 with peripheral sensory neuropathy, Peripheral sensory neuropathy due to type 2 diabetes mellitus, large and small fiber neuropathies, peripheral and proximal neuropathies, autonomic neuropathies, focal neuropathyDrug Interactions
THC Interaction with Pharmaceutical Drugs
- Tetrahydrocannabinol (THC) can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol.
- THC is metabolized by an inhibitor of several enzymatic liver pathways referred to as cytochrome P450 (aka CYP450). There are more than 50 enzymes belonging to this enzyme family, several of which are responsible for the breakdown of common drugs such as antidepressants (e.g., amitriptyline, doxepin, fluvoxamine), antipsychotics (haloperidol, clozapine, Stelazine), beta-blockers (e.g., propranolol), bronchodilators (e.g., theophylline), or blood thinners (e.g., warfarin). Thus, patients taking these medication classes may find that THC increases the concentration and effects of these drugs and the impact duration.
- Clinical observation (not yet confirmed by clinical trials) suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting CANN-DIR, published by Penn State College of Medicine.
CBD Interaction with Pharmaceutical Drugs
- Cannabidiol (CBD) may alter the action of metabolic enzymes (specific drug-transport mechanisms) and alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include anti-epileptics, psychiatric drugs, and drugs affecting metabolic enzymes.
- Clinical observations (not yet confirmed by clinical trials) suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD.
If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting CANN-DIR, published by Penn State College of Medicine.
THC/CBD Interaction with Pharmaceutical Drugs
In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.
If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting CANN-DIR, published by Penn State College of Medicine.
Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).
However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”
Dosing Considerations
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
